China Preeclampsia Laboratory Testing Market Analysis 2022-2027

1. China Preeclampsia Laboratory Testing Market Analysis, Business Segmentation, Outlook By 2027 Preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ dysfunction, poses significant challenges in diagnosis due to overlapping symptoms with normal pregnancies. However, the global preeclampsia laboratory testing market is set to witness robust growth between 2022 and 2027, driven by the increasing burden of preeclampsia and advancements in medical technologies. According to Fairfield Market Research, the market is expected to reach a value of US$17,386.1 million and witness a healthy CAGR of 4.6% during the forecast period. Access Full Report: https://www.fairfieldmarketresearch.com/report/preeclampsia- laboratory-testing-market

2. Developing countries, including China, are eyeing innovative diagnostic solutions for preeclampsia. The incidence of preeclampsia is estimated to be seven times higher in developing countries compared to developed ones, highlighting the urgent need for reliable and cost-effective screening tests. To address this unmet need, government institutions and academic organizations are collaborating with companies to develop new kits with lower costs. Early diagnostic tests for preeclampsia have the potential to minimize maternal and infant mortality rates. The growing awareness around preeclampsia, driven by patient advocacy groups and welfare associations such as the Preeclampsia Foundation and Accelerated Access Collaborative, presents lucrative opportunities for the development of innovative tests to meet the significant diagnostic needs worldwide. In China, researchers at the University of Strathclyde, in partnership with King's College London, have received funding and an Artificial Intelligence Health and Care award from the U.K. Government. These collaborations and the rapid emergence of innovative alternatives, such as handheld screening devices, are expected to boost the uptake of diagnostic tests in the preeclampsia laboratory testing market. The introduction of novel biomarkers shows promise for improving the diagnostic accuracy of preeclampsia and assessing its severity. Biomarkers have the potential to prevent unnecessary preterm births, hospitalizations, and medical interventions by providing greater precision and accuracy in diagnosis. The blood tests segment is expected to contribute approximately 41% to the global preeclampsia laboratory testing market in 2021. While developed countries, particularly North America and Europe, currently dominate the market due to technologically sophisticated diagnostic laboratories and early adoption of preeclampsia screening, Asia Pacific, including China, is expected to demonstrate high growth potential. The region's large population of women of reproductive age and increasing incidences of preeclampsia contribute to this growth. However, lack of awareness and reliable, cost-effective screening tests remain challenges in these regions. The decline in fertility rates globally and the introduction of interventions to lower the risk of developing preeclampsia may hinder the market's growth in the near future. However, market players, such as PerkinElmer Inc., Siemens Healthineers AG, and Thermo Fisher Scientific Inc., are prioritizing research and development (R&D) efforts and engaging in collaborative activities to strengthen their market positioning. Other prominent players in the preeclampsia laboratory testing market include F. Roche Hofmann Progenity, Inc., GestVision, Inc., Metabolomic Diagnostics Ltd., DiabetOmics Inc., DRG INSTRUMENTS GmbH, Lifeassay Diagnostics (Pty) Ltd, and Quidel Corporation, among others. Web: https://www.fairfieldmarketresearch.com/ Email: sales@fairfieldmarketresearch.com